FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
What happened
FDA investigators inspected Pine Pharmaceuticals, an outsourcing facility (a compounder registered with FDA to make sterile drugs without per-product approval), from November 4 to November 14, 2025, and issued a Form FDA 483 (the list of inspection observations) on November 14, 2025. They collected evidence that operators did not sanitize materials, equipment, hands, and sleeves when moving from the ISO 7 cleanroom into the ISO 5 sterile hood, and that routine environmental monitoring did not cover high-touch staging trays used before the ISO 5 area. FDA reviewed the company's December 8, 2025 response and found several corrective actions lacked documentation, root-cause analysis, or evidence of completion, and noted the aseptic technique problem is a repeat finding from inspections in May 2021, September 2023, and September 2024.
What FDA found
Operators did not sanitize materials, equipment, hands, or sleeves before putting them into the ISO 5 sterile hood, and one operator rested sleeved arms on support bars in the ISO 7 area and then reached into the ISO 5 area without sanitizing.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The environmental monitoring program does not routinely sample the high-touch staging trays that gloved operators use to hold materials and container closures before they go into the ISO 5 area, and the trays are hard to clean.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm did not thoroughly investigate unexplained discrepancies or batch failures, including a particulate complaint where cellulose and fibers were found and root cause was never determined.
21 CFR 211.192The firm did not establish and follow adequate written procedures to prevent microbiological contamination of products claimed to be sterile, including validation of aseptic processes.
21 CFR 211.113(b)The firm did not ensure each person involved in manufacturing had the education, training, and experience needed for their assigned tasks.
21 CFR 211.25(a)The firm did not determine actual and theoretical yields at each stage; batch records allowed a large share of a batch (amount redacted in the letter) to be rejected without triggering an investigation while the batch could still be released.
21 CFR 211.103
What FDA wants
Within 15 working days of receiving the letter, notify FDA in writing of the specific steps taken to correct the violations, with an explanation of each step to prevent recurrence and supporting documentation, or state why more time is needed and when the work will be done. FDA also strongly recommends management do a comprehensive assessment of operations, including aseptic processing, with help from a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- hospitals and clinics that buy compounded sterile drugs from outsourcing facilities
- brands and pharmacies that rely on contracted compounders for sterile products
- quality teams at other 503B outsourcing facilities with similar manual aseptic operations
This is a summary. Read the original letter on fda.gov.